Savara announces molgramostim nebulizer solution (molgramostim) achieved statistical significance for primary endpoint and multiple secondary endpoints in impala-2, a pivotal phase 3 clinical trial in autoimmune pulmonary alveolar proteinosis (apap)

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, phase 3 impala-2 clinical trial. impala-2 is a 48-week, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of molgramostim 300 mcg administered once daily by inhalation with matching placebo in adult patients with apap (nct04544293). molgramostim is an inhal.
SVRA Ratings Summary
SVRA Quant Ranking